Artiva Biotherapeutics (ARTV) News Today $7.07 +0.54 (+8.27%) Closing price 04:00 PM EasternExtended Trading$7.06 -0.01 (-0.14%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Financial Review: Aligos Therapeutics (NASDAQ:ALGS) and Artiva Biotherapeutics (NASDAQ:ARTV)January 13, 2025 | americanbankingnews.comArtiva Biotherapeutics, Inc.'s Lock-Up Period To Expire on January 15th (NASDAQ:ARTV)Artiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its IPO on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the expiration of Artiva Biotherapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.January 8, 2025 | marketbeat.comGeode Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Geode Capital Management LLC acquired a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 308,930 shares of the company'sJanuary 6, 2025 | marketbeat.comState Street Corp Acquires Shares of 86,559 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)State Street Corp bought a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 86,559 shares of the company's stock, valued at approximately $1,337,000. StateJanuary 3, 2025 | marketbeat.comResearch Analysts Issue Forecasts for ARTV FY2024 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - HC Wainwright issued their FY2024 EPS estimates for Artiva Biotherapeutics in a note issued to investors on Monday, December 30th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($6.00) for theJanuary 1, 2025 | marketbeat.comArtiva Biotherapeutics initiated with a Buy at H.C. WainwrightDecember 31, 2024 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Artiva Biotherapeutics (ARTV) with Buy RecommendationDecember 31, 2024 | msn.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Buy" from BrokeragesShares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have received an average recommendation of "Buy" from the five ratings firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating. The average 1-year price target aDecember 30, 2024 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Now Covered by HC WainwrightHC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a research note on Monday. They set a "buy" rating and a $20.00 target price for the company.December 30, 2024 | marketbeat.comFranklin Resources Inc. Purchases Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Franklin Resources Inc. acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 520,301 shares of the company's stock, valued at approxiDecember 23, 2024 | marketbeat.comWellington Management Group LLP Invests $2.91 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Wellington Management Group LLP bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 194,108 shares of the compaDecember 18, 2024 | marketbeat.comFDA ARMAT status for Affimed and Artiva’s lymphoma combo therapyDecember 6, 2024 | msn.comSamsara BioCapital LLC Acquires New Stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Samsara BioCapital LLC bought a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 291,666 shares of the company's stock, valued at approxDecember 5, 2024 | marketbeat.comRA Capital Management L.P. Takes $152.23 Million Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)RA Capital Management L.P. bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,853,302 shares of the company's stock, valued at approximately $152,234,000.December 5, 2024 | marketbeat.comRTW Investments LP Takes $2.30 Million Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)RTW Investments LP bought a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 148,844 shares of the company's stock, valued at approximately $December 5, 2024 | marketbeat.comAcuta Capital Partners LLC Takes $680,000 Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Acuta Capital Partners LLC purchased a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 44,000 shares of the company'sNovember 28, 2024 | marketbeat.comCantor Fitzgerald Forecasts ARTV FY2024 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer expects thaNovember 18, 2024 | marketbeat.comWedbush Has Bearish Forecast for ARTV FY2024 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush cut their FY2024 earnings per share estimates for Artiva Biotherapeutics in a research note issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per shareNovember 15, 2024 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Announces Earnings ResultsArtiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24).November 14, 2024 | marketbeat.comArtiva Biotherapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | tipranks.comArtiva Biotherapeutics, Inc.: Strong Buy Rating Supported by Robust Autoimmune Pipeline and Financial StabilityNovember 13, 2024 | markets.businessinsider.comNeedham & Company LLC Reiterates "Buy" Rating for Artiva Biotherapeutics (NASDAQ:ARTV)Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday.November 13, 2024 | marketbeat.comArtiva Biotherapeutics, Inc. (ARTV) Receives a Buy from TD CowenNovember 13, 2024 | markets.businessinsider.comArtiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 12, 2024 | globenewswire.comArtiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 11, 2024 | globenewswire.comArtiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of DirectorsOctober 22, 2024 | globenewswire.comArtiva Biotherapeutics (NASDAQ:ARTV) Shares Down 5.4% - Time to Sell?Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4% - Time to Sell?October 15, 2024 | marketbeat.comArtiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comBuy Rating Affirmed for Artiva Biotherapeutics on Promising AlloNK Developments and Trial OptimismSeptember 4, 2024 | markets.businessinsider.comArtiva Biotherapeutics (NASDAQ:ARTV) Rating Reiterated by WedbushWedbush reaffirmed an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday.August 31, 2024 | marketbeat.comBuy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong FinancialsAugust 30, 2024 | markets.businessinsider.comArtiva Biotherapeutics, Inc. (ARTV) Receives a Buy from WedbushAugust 30, 2024 | markets.businessinsider.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 30, 2024 | finanznachrichten.deArtiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 30, 2024 | markets.businessinsider.comThis Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative TreatmentAugust 29, 2024 | fool.comArtiva Biotherapeutics, Inc.'s (NASDAQ:ARTV) Quiet Period Will End on August 28thArtiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) quiet period is set to expire on Wednesday, August 28th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. During Artiva Biotherapeutics' quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.August 21, 2024 | marketbeat.comArtiva Biotherapeutics shares get Overweight ratingAugust 15, 2024 | uk.investing.comAnalysts Set Expectations for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV)Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Research analysts at Wedbush issued their Q2 2024 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Tuesday, August 13th. Wedbush analyst D. Nierengarten expects that the company will earn ($1.5August 15, 2024 | marketbeat.comArtiva Biotherapeutics, Inc. (ARTV)August 13, 2024 | finance.yahoo.comBuy Rating Affirmed: Artiva Biotherapeutics’ Promising AlloNK Cell Therapy in the Autoimmune SpaceAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Artiva Biotherapeutics Amid Promising NK Cell Therapy DevelopmentsAugust 13, 2024 | markets.businessinsider.comArtiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish PitchAugust 13, 2024 | benzinga.comJefferies Financial Group Begins Coverage on Artiva Biotherapeutics (NASDAQ:ARTV)Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research report on Tuesday. They set a "buy" rating and a $21.00 price target for the company.August 13, 2024 | marketbeat.comArtiva Biotherapeutics Inc ARTVJuly 31, 2024 | morningstar.comInsider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up SharesJuly 28, 2024 | 247wallst.comArtiva Biotherapeutics Inc (ARTV)July 23, 2024 | investing.comInsider Buying: Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Buys 416,666 Shares of StockJuly 23, 2024 | insidertrades.com Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTV Media Mentions By Week ARTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTV News Sentiment▼0.000.57▲Average Medical News Sentiment ARTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTV Articles This Week▼01▲ARTV Articles Average Week Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CDMO News SANA News TYRA News AVDL News SEPN News CRON News IMTX News REPL News BCAX News PLRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTV) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
